Last checked at 1 Apr 2010 15:54
| For Immediate Release | 1 April 2010 |
Oxford BioMedica plc ("Oxford BioMedica" or the "Company")
Annual Information Update for the Twelve Months to 1 April 2010
Oxford BioMedica is providing an annual information update pursuant to Prospectus Rule 5.2 made by the Financial Services Authority.
1. Announcements made via a Regulatory Information Service
| Date | Announcement |
|
|
|
| 14 April 2009 | Holding(s) in Company |
| 17 April 2009 | Holding(s) in Company |
| 29 April 2009 | New development collaboration with Sanofi-aventis for ocular diseases |
| 29 April 2009 | Termination of development collaboration for TroVax |
| 1 May 2009 | Holding(s) in Company |
| 11 May 2009 | Update on patent infringement litigation |
| 14 May 2009 | Interim management statement |
| 28 May 2009 | Blocklisting interim review |
| 29 May 2009 | Total voting rights update |
| 1 June 2009 | Update on Phase I/II and II TroVax clinical trials |
| 4 June 2009 | AGM result |
| 18 June 2009 | Corporate presentation at Piper Jaffray Europe conference |
| 18 June 2009 | Holding(s) in Company |
| 19 June 2009 | Holding(s) in Company (amendment) |
| 6 July 2009 | Outcome of FDA review of TroVax |
| 13 July 2009 | ProSavin clinical trial update |
| 5 August 2009 | Notice of interim results |
| 6 August 2009 | Analyst meeting - change of time |
| 7 August 2009 | Corporate presentation at Canaccord Adams Global Growth Conference |
| 19 August 2009 | Notice that TroVax Phase III data will be presented at ECCO/ESMO conference |
| 27 August 2009 | Interim results |
| 28 August 2009 | Total voting rights update |
| 1 September 2009 | Director's interest in shares |
| 4 September 2009 | Corporate presentation at Rodman & Renshaw conference |
| 22 September 2009 | TroVax Phase III data presented at ECCO/ESMO conference |
| 30 September 2009 | Total voting rights update |
| 15 October 2009 | ProSavin clinical trial update |
| 19 October 2009 | Holding(s) in Company |
| 30 October 2009 | Total voting rights update |
| 19 November 2009 | Interim management statement |
| 27 November 2009 | Blocklisting interim review |
| 3 December 2009 | Holding(s) in Company |
| 15 December 2009 | Orphan Drug designation granted for StarGen in Europe |
| 5 January 2010 | Management and Board changes |
| 20 January 2010 | Orphan Drug designation granted for UshStat in Europe |
| 22 January 2010 | Purchase of patent rights and issue of shares |
| 27 January 2010 | Settlement of patent litigation with Bavarian Nordic |
| 27 January 2010 | Extension of research collaboration in motor neurone disease |
| 29 January 2010 | Total voting rights update |
| 17 February 2010 | Notice of results |
| 26 February 2010 | Total voting rights update |
| 10 March 2010 | Preliminary results for 2009 |
| 29 March 2010 | 2009 annual report & accounts and AGM notification |
| 31 March 2010 | Total voting rights update |
| 1 April 2010 | Annual information update |
Details of all regulatory announcements for Oxford BioMedica can be found on the London Stock Exchange website at www.londonstockexchange.com and on the Oxford BioMedica website at http://www.oxfordbiomedica.co.uk
2. Documents filed with Companies House
| Date | Document Type | Description |
|
|
|
|
| 4 June 2009 | AGM Special Business | AGM minutes |
| 18 September 2009 | 88(2) Return of Allotment of shares | Allotment 1,658,052 1p Ord. |
| 24 September 2009 | 363a Annual Return | Annual return |
| 7 December 2009 | SH01 Return of Allotment of shares | Allotment 28,973 1p Ord. |
Copies of documents filed at Companies House can be obtained from Companies House, Crown Way, Cardiff CF14 3UZ or through Companies House Direct at www.direct.companieshouse.gov.uk
3. Documents published or sent to shareholders or filed with the UKLA Viewing Facility
| Date | Description |
| 9 September 2009 | Interim Report for 6 months to 30 June 2009 |
| 29 March 2010 | Annual report for the year ended 31 December 2009 |
Copies of all the above documents may be obtained from the Company Secretary at the Company's Registered Office:
This annual information update is filed pursuant to Prospectus Rule 5.2 made by the Financial Services Authority and not for any other purpose and by filing this annual information update neither the Company, nor any other person, takes any responsibility for, or makes any representation, express or implied, as to the accuracy or completeness of, the information contained or referred to below herein. The information referred to below is not necessarily up to date as at the date of this annual information update and the Company does not undertake any obligation to update any such information in the future. Furthermore, such information may have been prepared in accordance with the laws or regulations of a particular jurisdiction and may not comply with or meet the relevant standards of disclosure in any other jurisdiction. Neither this annual information update, nor the information referred to below constitutes, by virtue of this communication, an offer of any securities addressed to any person and should not be relied on by any person.
Oxford BioMedica plc
Medawar Centre
Robert Robinson Avenue
The Oxford Science Park
Oxford
OX4 4GA
1 April 2010